It is planned to enroll 14 subjects who will receive single oral doses of active IMP in a sequential manner over 5 periods, with a minimum of 7days between dosing in each period.
This is a single centre, open-label, 5-period study in healthy male and non-pregnant and non-lactating healthy female subjects.